

sections G, H, and I of the amended PA 02060.

### E. Submission and Deadline

#### Letter of Intent

On or before February 5, 2003, submit the LOI to the Grants Management Specialist identified in the "Where to Obtain Additional Information" section of this announcement.

#### Application

Submit the signed original and two copies of CDC Form 0.1246. Forms are available at the following Internet address: [www.cdc.gov/od/pgo/forminfo.htm](http://www.cdc.gov/od/pgo/forminfo.htm). If you do not have access to the Internet, or if you have difficulty accessing the forms on-line, you may contact the CDC Procurement and Grants Office Technical Information Management Section at: 770-488-2700. Application forms can be mailed to you.

The application must be received by 4 p.m. eastern time March 7, 2003. Submit the application to: Technical Information Management-PA02060-FY03, CDC Procurement and Grants Office, 2920 Brandywine Road, Room 3000, Atlanta, GA 30341-4146.

Applications may not be submitted electronically.

Please reference Program Announcement Number 02060-FY03 National Cancer Prevention and Control Program on the mailing envelope and on the application Standard Form 424, block 11. Please also make sure that block 16 on Standard Form 424 regarding Executive Order 12372 has been completed correctly.

#### Deadline

Letters of intent and applications shall be considered as meeting the deadline if they are received before 4 p.m. eastern time on the deadline date. Any applicant who sends their application by the United States Postal Service or commercial delivery services must ensure that the carrier will be able to guarantee delivery of the application by the closing date and time. If an application is received after closing due to (1) Carrier error, when the carrier accepted the package with a guarantee for delivery by the closing date and time, or (2) significant weather delays or natural disasters, CDC will upon receipt of proper documentation, consider the application as having been received by the deadline.

Any application that does not meet the above criteria will not be eligible for competition, and will be discarded. The applicant will be notified of their failure to meet the submission requirements.

### F. Evaluation Criteria

Each application will be evaluated individually, through an objective review process.

For specific evaluation criteria information, please see sections G, H, and I of the amended PA 02060.

#### Where To Obtain Additional Information

This, and other CDC announcements can be found on the CDC home page, Internet address: <http://www.cdc.gov>.

Click on "Funding" then "Grants and Cooperative Agreements."

For general questions about this announcement, contact: Technical Information Management, CDC Procurement and Grants Office, 2920 Brandywine Road, Room 3000, Atlanta, GA 30341-4146. Telephone: 770-488-2441.

For business management and budget assistance, contact: Annie Camacho or Glynnis Taylor, Grants Management Specialist, CDC Procurement and Grants Office, 2920 Brandywine Road, Room 3000, Atlanta, GA 30341-4146.

Telephone: Annie Camacho: 770-488-2735. Glynnis Taylor: 70-488-2752.

E-mail address: Annie Camacho: [atc4@cdc.gov](mailto:atc4@cdc.gov). Glynnis Taylor: [gld1@cdc.gov](mailto:gld1@cdc.gov).

For business management and budget assistance in the territories, contact: Charlotte Flitcraft, Grants Management Officer, CDC Procurement and Grants Office, 2920 Brandywine Road, Room 3000, Atlanta, GA 30341-4146. Telephone: 770-488-2632. E-mail address: [caf5@cdc.gov](mailto:caf5@cdc.gov).

For program technical assistance contact:

#### NCCCP:

Leslie S. Given, M.P.A., Public Health Advisor, NCCCP, Program Services Branch, Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, 4770 Buford Hwy., NE. (MS K-57), Atlanta, GA 30341-3717. Telephone number: 770-488-3099. E-mail address: [llg5@cdc.gov](mailto:llg5@cdc.gov).

#### NBCCEDP:

Susan True, M.Ed., Branch Chief, Program Services Branch, Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, 4770 Buford Hwy., NE. (MS K-57), Atlanta, GA 30341-3717. Telephone number: 770-488-4880. E-mail address: [smt7@cdc.gov](mailto:smt7@cdc.gov).

#### NPCR:

Leah Simpson, M.B.A., Program Analyst, Cancer Surveillance Branch, Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, 4770 Buford Hwy., NE. (MS K-53), Atlanta, GA 30341-3717. Telephone number: 770-488-4158. E-mail address: [lds0@cdc.gov](mailto:lds0@cdc.gov).

Dated: January 13, 2003.

#### Sandra R. Manning,

CGFM, Director, Procurement and Grants Office, Centers for Disease Control and Prevention.

[FR Doc. 03-1192 Filed 1-17-03; 8:45 am]

BILLING CODE 4163-18-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. 02N-0309]

### Agency Information Collection Activities; Announcement of OMB Approval; Reclassification Petitions for Medical Devices

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing that a collection of information entitled "Reclassification Petitions for Medical Devices" has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.

#### FOR FURTHER INFORMATION CONTACT:

Peggy Robbins, Office of Information Resources Management (HFA-250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-1223.

**SUPPLEMENTARY INFORMATION:** In the *Federal Register* of October 16, 2002 (67 FR 63932), the agency announced that the proposed information collection had been submitted to OMB for review and clearance under 44 U.S.C. 3507. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910-0138. The approval expires on January 31, 2006. A copy of the supporting statement for this information collection is available on the Internet at <http://www.fda.gov/ohrms/dockets>.

Dated: January 14, 2003.

**Margaret M. Dotzel,**

*Assistant Commissioner for Policy.*

[FR Doc. 03-1256 Filed 1-17-03; 8:45 am]

BILLING CODE 4160-01-S

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. 00N-1526]

#### Robert A. Fiddes; Debarment Order; Correction

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice; correction.

**SUMMARY:** The Food and Drug Administration (FDA) is correcting a notice that appeared in the **Federal Register** of November 6, 2002 (67 FR 67628). The document announced the issuance of an order under the Federal Food, Drug, and Cosmetic Act debaring Dr. Robert A. Fiddes for 20 years from providing services in any capacity to a person that has an approved or pending drug product application. The document was published with an inadvertent error. This document corrects that error.

**FOR FURTHER INFORMATION CONTACT:** Joyce Strong, Office of Policy (HF-27), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-7010.

**SUPPLEMENTARY INFORMATION:** In FR Doc. 02-28256, appearing on page 67628 in the **Federal Register** of Wednesday, November 6, 2002, the following correction is made:

1. On page 67628, in the second column, under "II. Findings and Order", in the fourth and fifth lines, "(21 CFR 5.99)" is corrected to read "(21 CFR 5.34)".

Dated: January 14, 2003.

**Margaret M. Dotzel,**

*Assistant Commissioner for Policy.*

[FR Doc. 03-1255 Filed 1-17-03; 8:45 am]

BILLING CODE 4160-01-S

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

#### Vaccines and Related Biological Products Advisory Committee; Notice of Meeting

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). At least one portion of the meeting will be closed to the public.

**Name of Committee:** Vaccines and Related Biological Products Advisory Committee.

**General Function of the Committee:** To provide advice and recommendations to the agency on FDA's regulatory issues.

**Date and Time:** The meeting will be held on February 20, 2003, from 8:30 a.m. to 4:30 p.m.

**Location:** Holiday Inn, 8120 Wisconsin Ave., Bethesda, MD.

**Contact Person:** Jody G. Sachs or Denise H. Royster, Center for Biologics Evaluation and Research (HFM-71), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, 301-827-0314, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12391. Please call the Information Line for up-to-date information on this meeting.

**Agenda:** The committee will review and discuss the selection of strains to be included in the influenza virus vaccine for the 2003-2004 season and the intramural research program of the Laboratory of Bacterial Polysaccharides, Office of Vaccines Research and Review.

**Procedure:** On February 20, 2003, from 8:30 a.m. to 3:20 p.m., the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by February 4, 2003. Oral presentations from the public will be scheduled between approximately 1 p.m. and 1:30 p.m. and 2:50 p.m. and 3:20 p.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before February 4, 2003, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

**Closed Committee Deliberations:** On February 20, 2003, from 3:20 p.m. to 4:30 p.m., the meeting will be closed to permit discussion where disclosure would constitute a clearly unwarranted invasion of personal privacy (5 U.S.C. 552b(c)(6)).

Persons attending FDA's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Jody G. Sachs or Denise H. Royster at least 7 days in advance of the meeting.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: January 10, 2003.

**Linda Arey Skladany,**

*Associate Commissioner for External Relations.*

[FR Doc. 03-1208 Filed 1-17-03; 8:45 am]

BILLING CODE 4160-01-S

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Office of Inspector General; Program Exclusions: December 2002

**AGENCY:** Office of Inspector General, HHS.

**ACTION:** Notice of program exclusions.

During the month of December 2002, the HHS Office of Inspector General imposed exclusions in the cases set forth below. When an exclusions is imposed, no program payment is made to anyone for any items or services (other than an emergency item or service not provided in a hospital emergency room) furnished, ordered or prescribed by an excluded party under the Medicare, Medicaid, and all Federal Health Care programs. In addition, no program payment is made to any business or facility, e.g., a hospital, that submits bills for payment for items or services provided by an excluded party. Program beneficiaries remain free to decide for themselves whether they will continue to use the services of an excluded party even though no program payments will be made for items and services provided by that excluded party. The exclusions have national effect and also apply to all Executive Branch procurement and non-procurement programs and activities.

Subject city, state	Effective date
<b>PROGRAM-RELATED CONVICTIONS</b>	
ALY, WAEL .....	01/20/2003
CLIFTON, NJ	
BACO-CUEBAS, GERMAN A ..	01/20/2003
MAYAGUEZ, PR	
BERG, SHANNON GRIFFIN ....	01/20/2003
FLORENCE, SC	
BRIDGER, BARBARA LYNN ...	01/20/2003
PIERRE, SD	
CHRISTOPHERSON, PAUL K	01/20/2003